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Purpose: Although current guidelines recommend continuing the same antithrom-
botic strategy regardless of rhythm control after radiofrequency catheter ablation 
(RFCA) of atrial fibrillation (AF), anticoagulation has a risk of major bleeding. We 
evaluated the safety of switching warfarin to aspirin in patients with successful AF 
ablation. Materials and Methods: Among 721 patients who underwent RFCA of 
AF, 608 patients (age, 57.3±10.9 years; 77.0% male, 75.5% paroxysmal AF) who 
had no evidence of AF recurrence at 3 months post-RFCA were included. We com-
pared the thromboembolic and hemorrhagic events in patients for whom warfarin 
was switched to aspirin (ASA group; n=296) and patients who were kept on warfarin 
therapy (W group; n=312). Results: There were no significant differences in 
CHA2DS2-VASc or HAS-BLED scores between the groups. In 30 patients in the 
ASA group and 37 patients in W group, AF recurred and warfarin was restarted or 
maintained during the 18.0±12.2 months of follow-up. There were no significant dif-
ferences in thromboembolic (0.3% vs. 1.0%, p=0.342) and major bleeding incidenc-
es (0.7% vs. 0.6%, p=0.958) between ASA and W groups during the follow-up peri-
od. In the 259 patients with a CHA2DS2-VASc score ≥2, there were no significant 
differences in thromboembolism (0.8% and 2.2%, p=0.380) or major bleeding inci-
dences (0.8% and 1.4%, p=0.640) between ASA and W groups. Conclusion: 
Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe 
and efficacious as long-term anticoagulation even in patients with CHA2DS2-VASc 
score ≥2. However, strict rhythm monitoring cannot be overemphasized.
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INTRODUCTION
Atrial fibrillation (AF) is significantly associated with the risk of strokes,1,2 and 
given this association, antithrombotic therapy is essential in the management of 
AF. CHADS2 or CHA2DS2-VASc scores have been utilized for risk stratification 
of ischemic stroke in patients with AF,3,4 and anticoagulation is recommended for 
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follows: 1) permanent AF refractory to electrical cardiover-
sion; 2) left atrium (LA) size >55 mm as measured by 
echocardiogram; 3) critical coronary artery stenosis (>75% 
of luminal diameter); 4) severe rheumatic mitral valvular 
disease; and 5) prior RFCA of AF. Three-dimensional (3D) 
spiral computerized tomography (CT) scans (64 Channel, 
Light Speed Volume CT, Philips, Brilliance 63, the Nether-
lands) were performed to visually define pulmonary vein 
(PV) anatomy. The presence of an LA thrombus was ex-
cluded by transesophageal echocardiography. All AADs 
were discontinued for a period corresponding to at least 
five half-lives. In total, 141 patients (19.6%) were taking 
amiodarone, which was discontinued for at least four weeks 
prior to the procedure. Anticoagulation therapy was main-
tained before RFCA for all patients. 
Electrophysiologic mapping and radiofrequency 
catheter ablation
Intracardiac electrograms were recorded using the Prucka 
CardioLabTM electrophysiology system (General Electric 
Health Care System Inc., Milwaukee, WI, USA) or Work-
mate (St. Jude Medical Inc., Minnetonka, MN, USA). 
RFCA was performed in all patients using 3D electroana-
tomical mapping (NavX; St. Jude Medical Inc., Minneton-
ka, MN, USA or Carto; Johnson & Johnson Inc., Diamond 
Bar, CA, USA) merged with 3D spiral CT. We used an 
open irrigated-tip catheter (Celsius or Thermocool, Johnson 
& Johnson Inc.; Diamond Bar, CA, USA; irrigation flow 
rate 20 to 30 mL/min; 25--35 W; 47°C) to deliver radiofre-
quency energy for ablation (Stockert generator, Biosense 
Webster Inc.; Diamond Bar, CA, USA). All patients initially 
underwent circumferential PV isolation (CPVI) and bi-direc-
tional block of the cavotricuspid isthmus. For the patients 
with PAF, we added linear ablations and complex fractionat-
ed atrial electrogram (CFAE) ablation guided by 3D-CFAE-
CL map15 in a stepwise approach in patients without AF ter-
mination during RFCA. For PeAF, we conducted CPVI, 
cavotricuspid isthmus block, roof line, posterior inferior line, 
and anterior line16 as a routine lesion set, and CFAE ablation 
was added based on the operator’s decision. If AF persisted 
beyond the aforementioned ablation protocols for PAF or 
PeAF, we stopped the procedure after internal cardioversion. 
The endpoint of our procedure was no immediate recurrence 
of  AF after cardioversion with isoproterenol infusion (5--20 
µg/min). If there were non-PV foci under isoproterenol, we 
ablated them all. During RFCA, activated clotting time was 
maintained between 350 to 400 seconds. 
the patients with CHADS2 score ≥1 or CHA2DS2-VASc 
score ≥1.5,6 Radiofrequency catheter ablation (RFCA) has 
been known to be as effective as or more effective than an-
tiarrhythmic drugs (AAD) at controlling rhythm in AF pa-
tients.7-9 According to the 2012 HRS/EHRA/ECAS Expert 
Consensus Statement, AAD-resistant symptomatic parox-
ysmal AF (PAF) and persistent AF (PeAF) are class I and 
IIa indications for RFCA, respectively.10 However, the same 
guidelines recommend that anticoagulation be continued 
after RFCA of AF based on CHADS2 or CHA2DS2-VASc 
score.10 Although warfarin is effective for the prevention of 
stroke in patients with AF, using warfarin is difficult given 
the various dose-effect relationships as well as potential 
drug-drug or drug-food interactions. Moreover, warfarin in-
troduces an annual risk of major bleeding of 3.1--3.7%.11-13 
Of the various bleeding risk stratification schemas, the HAS-
BLED score is recommended by the current guidelines for 
prediction of bleeding risk in patients who take warfarin due 
to AF,5,14 and special attention should be paid to patients 
with high HAS-BLED score. Given the risks and benefits of 
warfarin, controversies remain regarding long-term use of 
warfarin after successful RFCA of AF. Therefore, we hy-
pothesized that switching warfarin to aspirin (ASA group) 
may have an equivalent efficacy and safety in the prevention 
of ischemic stroke, compared with continuous warfarin ad-
ministration (W group) in patients with no evidence of AF 
recurrence after RFCA during standard rhythm monitoring. 
MATERIALS AND METHODS
　　　
Study population
The study protocol was approved by the Institutional Re-
view Board of Severance Cardiovascular Hospital, Yonsei 
University Health System and Asan Medical Center, and 
adhered to the Declaration of Helsinki. This study included 
721 patients who were prospectively registered in a data-
base of AF catheter ablation between March 2009 and De-
cember 2011 in two centers. Clinical outcomes, thromboem-
bolic events, and hemorrhagic complications were compared 
between the ASA group and the W group in the registry da-
tabase. Among these 721 patients, there were 608 patients 
(age, 57.3±10.9 years; 77.0%, male; 75.5%, PAF; 24.5%, 
PeAF) who had no evidence of AF recurrence on Holter 
monitoring 3 months after RFCA in this study. All patients 
provided written informed consent, and all were AAD-re-
sistant or intolerant patients. The exclusion criteria were as 
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quiring blood transfusion or intervention, and bleeding with 
reduction of hemoglobin levels by ≥4.0 g/dL.18 We compared 
incidences, hazard ratio and event-free survival of thrombo-
embolic events (including stroke, TIA, and other thrombo-
embolism) and major bleeding events between ASA and W 
groups depending on CHA2DS2-VASc score. 
Statistical analyses 
The results are expressed as mean±standard deviation. The 
Student’s t-test, χ2 test were used for comparison of inci-
dences of primary endpoints between the groups. Univari-
ate and multivariate Cox regression analyses were used for 
comparison of hazard ratio (HR) between the groups. The 
assumption was assessed by log-minus-log-survival func-
tion and found that the proportion hazards assumption was 
reasonable. Parameters of a p value ≤0.1 by univariate anal-
ysis were included for multivariate analysis. HRs and 95% 
confidence intervals (CIs) were calculated. The Kaplan-Mei-
er method was used for analyzing event-free survival. A p 
value <0.05 was considered significant. The data were ana-
lyzed using the Statistical Package for the Social Sciences 
version 20.0 (IBM Inc., Armonk, NY, USA).
RESULTS
 
Patient characteristics 
Patient demographic and clinical characteristics in the ASA 
and W groups at baseline were shown (Table 1). There were 
no significant differences in clinical profiles, LA size, and left 
ventricular function. CHADS2, CHA2DS2-VASc, and HAS-
BLED scores were not significantly different between two 
groups. However, past history of stroke/TIA was more fre-
quent in the W group (14.5%) than in the ASA group (7.1%, 
p=0.006). The time in the therapeutic range of international 
normalized ratio (INR) for the W group was 44.2% during 
the follow-up period. In sixty-seven patients (6.1%), AF re-
Post-RFCA follow-up 
All patients were followed up at the outpatient clinic after 1, 
3, 6, 9, and 12 months post-RFCA and then every 6 months. 
Electrocardiography (ECG) was performed at every visit 
and whenever the patients complained of palpitation. A 
Holter monitoring (24- or 48-hour) and/or an event recorder 
were performed at 3, 6, 12, 18, and 24 months after RFCA 
and whenever patients complained of palpitation following 
the 2012 HRS/EHRA/ECAS Expert Consensus Statement 
guidelines.10 We defined recurrence of AF as any episode of 
AF or atrial tachycardia of at least 30 sec in duration.17 If any 
ECG-documented AF episode occurred within the three-
month blanking period during follow-up, patients were then 
diagnosed as an early recurrence, and any AF recurrence 
thereafter was diagnosed as clinical recurrence.17 In case of 
early recurrence and clinical recurrence, AADs were pre-
scribed. 
Comparisons of ASA switching and continuous 
warfarin during follow-up
A total of 608 patients without evidence of AF recurrence 
on ECG and Holter monitoring at 3 months after RFCA 
were included in this study. We compared the thromboem-
bolic events and major bleeding complications in 296 pa-
tients for whom warfarin was changed to 100 mg of aspirin 
(ASA group) and 312 patients for whom anticoagulation 
was maintained (W group) after confirming no recurrence 
in the 3rd-month post-RFCA Holter monitoring (Fig. 1). 
The primary endpoints were thromboembolism including 
ischemic stroke/transient ischemic attack (TIA) and major 
bleeding after 3 months from RFCA. Stroke was defined as 
symptomatic ischemic cerebral infarction with apparent 
brain lesion in imaging studies. TIA was defined as a tran-
sient episode of neurologic dysfunction confirmed by a 
neurologist without brain lesion in imaging studies, with 
spontaneous symptomatic recovery within 24 hours. Major 
bleeding events were defined as any type of hemorrhage re-
Fig. 1. Flow diagram and numbers of patients. AF, atrial fibrillation; RFCA, radiofrequency catheter ablation.
Not regularly followed up (n=12)
RFCA of AF (n=721)
Success at 3 months (n=608)
ASA group (n=296)
Recurrence at 3 months (n=101)
W group (n=312)
Warfarin after Successful AF Ablation 
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CHA2DS2-VASc score (HR, 3.80; 95% CI, 1.13--12.71; 
p=0.031) was an independent risk factor for thromboembolic 
events, and HAS-BLED score (HR, 3.90; 95% CI, 1.13--
13.45; p=0.031) was an independent risk factor for major 
bleeding events (Table 3). By Kaplan-Meier analysis, there 
were no significant differences of event-free survival from 
the composite primary endpoint (thromboembolic and major 
bleeding events) between the groups (p=0.968) (Fig. 2A). 
Comparisons in patients with CHA2DS2-VASc score ≥2
Among the 608 included patients, 259 patients (42.6%) had a 
CHA2DS2-VASc score ≥2 (ASA group, 121; W group, 138). 
Table 4 shows comparison of clinical characteristics of the 
patients with CHA2DS2-VASc score ≥2 in the ASA and W 
groups. The patients in the W group were younger (62.9±9.0 
years vs. 65.5±8.3 years, p=0.019) and more likely to have 
had a history of stroke/TIA (32.6% vs. 17.3%, p=0.008) than 
the patients in the ASA group. In patients with CHA2DS2-
curred after 3 months of post-RFCA. After recurrence of AF, 
warfarin was restarted according to CHA2DS2-VASc score. 
Hemorrhagic and thromboembolic risks were not 
different between ASA and W groups
During the 18.0±12.2 months of follow-up, stroke occurred 
in a patient in the ASA group (0.3%). Stroke and TIA oc-
curred in one and two patients in the W group, respectively 
(1.0%, p=0.342). All patients who experienced a stroke re-
covered without sequelae. In all patients with thromboem-
bolic complications, heart rhythm was sinus rhythm at the 
time of stroke or TIA. Major bleeding events occurred in 
two patients in ASA and W groups (0.7% and 0.6%, re-
spectively; p=0.958). The detailed information about events 
in each patient was shown (Table 2). There were no throm-
boembolic or major bleeding complications in patients with 
AF recurrence. 
In univariate and multivariate Cox regression analyses, 
Table 1. Baseline Characteristics of All Patients
ASA group (n=296) W group (n=312) p value
Age (yrs)   56.9±11.7   57.6±10.1 0.453
Male sex (%) 77.7 76.3 0.677
PAF (%) 75.7 75.3 0.919
CHADS2 score   0.91±0.98   1.04±1.04 0.089
CHA2DS2-VASc score   1.45±1.34   1.55±1.36 0.335
HAS-BLED score   1.37±0.83   1.45±1.02 0.268
LA diameter (mm) 41.2±6.0 42.9±7.2 0.002
Ejection fraction (%) 63.1±8.7 61.8±8.6 0.066
Prior aspirin use (%) 21.3 26.6 0.125
Comorbidities (%)
    Hypertension 53.4 53.2 0.966
    Diabetes 13.9 16.0 0.453
    Stroke/TIA   7.1 14.5 0.006
    Chronic kidney disease   1.0   1.3 0.756
    Heart failure   4.1   2.6 0.303
LA, left atrium; PAF, paroxysmal atrial fibrillation; TIA, transient ischemic attack.
Table 2. Patients with Primary Endpoints
Group Age/sex AF type
CHA2DS2-
VASc score
HAS-BLED 
score
Primary endpoints
Time to event 
(month)
INR at event
ASA 60/F Paroxysmal 3 1 Stroke; occipital 7 0.91
ASA 73/M Paroxysmal 5 4 Pseudoaneurysm rupture 3.1 0.95
ASA 49/M Paroxysmal 0 1 Epistaxis 3.3 1.12
W 42/M Paroxysmal 2 1 Stroke; frontal 25 4.82
W 62/M Persistent 2 1 TIA 6 1.19
W 71/F Paroxysmal 4 1 TIA 28 2.61
W 62/F Paroxysmal 3 3 Intramuscular hematoma 4 6.22
W 69/F Paroxysmal 4 3 Gingival bleeding 4 2.28
AF, atrial fibrillation; INR, international normalized ratio; TIA, transient ischemic attack.
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mary endpoint in the patients with CHA2DS2-VASc score 
≥2 between the groups (p=0.822) (Fig. 2B). 
DISCUSSION
This is a retrospective observational study that evaluated the 
VASc score ≥2, thromboembolic events occurred in one pa-
tient in the ASA group (0.8%) and three patients in the W 
group (2.2%, p=0.380), respectively during follow-up peri-
od. Major bleeding events occurred in one and two patients 
in the ASA (0.8%) and W groups (1.4%, p=0.640), respec-
tively. By Kaplan-Meier analysis, there were no significant 
differences of event-free survival from the composite pri-
Table 3. Clinical Factors Related to Thromboembolic or Major Bleeding Events by Multivariate Cox Regression Analysis
Thromboembolism Bleeding
HR (95% CI) p value HR (95% CI) p value
Age 0.96 (0.85--1.08) 0.452 0.96 (0.85--1.08) 0.466
Male sex 0.83 (0.10--6.90) 0.865 0.23 (0.03--1.50) 0.123
CHA2DS2-VASc score   3.80 (1.13--12.71) 0.031 1.23 (0.44--3.41) 0.691
HAS-BLED score 0.24 (0.04--1.42) 0.115   3.90 (1.13--13.45) 0.031
Warfarin duration   0.89 (0.65--12.16) 0.931 0.86 (0.16--4.61) 0.863
CI, confidence interval; HR, hazard ratio.
Table 4. Baseline Characteristics of Patients with CHA2DS2-VASc Score ≥2
ASA group (n=121) W group (n=138) p value
Age (yrs) 65.5±8.3 62.9±9.0 0.019
Male sex (%) 64.5 60.9 0.551
PAF (%) 72.7 73.2 0.934
CHADS2 score   1.69±0.99   1.89±0.92 0.098
CHA2DS2-VASc score   2.78±1.00   2.82±0.98 0.734
HAS-BLED score   1.89±0.83   1.96±1.13 0.601
LA diameter (mm) 42.5±6.1 43.5±6.5 0.216
Ejection fraction (%)   63.1±10.0 61.9±8.9 0.345
Prior aspirin use (%) 23.5 29.7 0.287
Comorbidities (%)
    Hypertension 83.5 76.8 0.182
    Diabetes 29.8 33.3 0.536
    Stroke/TIA 17.3 32.6 0.008
    Chronic kidney disease   2.5   1.4 0.548
    Heart failure   9.1   5.1 0.205
LA, left atrium; PAF, paroxysmal atrial fibrillation; TIA, transient ischemic attack.
Fig. 2. Thromboembolic and major bleeding event-free survival by Kaplan-Meier method in all patients (A) and the patients with CHA2DS2-VASc score ≥2 (B) 
in ASA (solid line) and W (dotted line) groups. 
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stroke (CHADS2 score), such as hypertension, old age, or 
previous stroke. In spite of ethnical similarity, major bleed-
ing rates were 1.6% in JAST and 0.7% in current study. 2010 
EHRA-EAPCI Consensus Documents recommended using 
warfarin monotherapy in patients with AF and percutane-
ous coronary intervention who are stable longer than 1 year.23 
However, whether warfarin monotherapy is safe enough to 
prevent an annual 2.8% risk of very late stent thrombosis in 
patients with drug-eluting stents24 and major hemorrhagic 
complications remains unclear.   
Anticoagulation issue after rhythm control of AF
The main reason for continuing oral anticoagulation after 
successful RFCA is the concern for asymptomatic AF re-
currence.10 Previous studies have shown a 0.5 to 7% risk of 
stroke or thromboembolic events after RFCA of AF,25-27 and 
current guidelines suggest anticoagulation should be main-
tained even after successful RFCA of AF according to 
CHADS2 or CHA2DS2-VASc score.10 However, there have 
been efforts to stop anticoagulation after potentially suc-
cessful RFCA of AF because of the bleeding risks and in-
convenience of warfarin. There have been several studies 
demonstrating incidence of thromboembolic events decrease 
after successful RFCA of AF.28-30 Oral, et al.25 showed that, 
among 755 successfully ablated AF patients, discontinua-
tion of anticoagulation therapy was safe in patients younger 
than 65 years without a history of stroke. Bunch, et al.31 
demonstrated the safety of 325 mg aspirin without warfarin 
in 690 patients with CHADS2 score 0 to 1, and Saad, et al.32 
reported that no thromboembolic morbidity without antico-
agulation existed in 327 patients with CHADS2 score ≤3. 
However, in a prior nonrandomized study of 3355 patients 
who underwent CPVI, suspension of oral anticoagulation 
therapy after successful RFCA was beneficial in patients at 
moderate to high risk of thromboembolism.30 Therefore the 
decision to anticoagulate after successful RFCA should be 
based on assessment of the risk-benefit ratio, and switching 
anticoagulation to aspirin can be considered in patients with 
high risk of hemorrhage and no recurrence of AF. There 
were two reasons that we grouped the patients based on an-
ticoagulation therapy 3 months after RFCA. First, the cur-
rent guidelines recommend that warfarin should be contin-
ued for 2 months after RFCA. Second, post-procedural 3 
months are considered as blanking period and not consid-
ered as clinical recurrence.33 
However, strict rhythm monitoring cannot be overem-
phasized. In this study, heart rhythm was sinus rhythm at 
risk and benefit of switching anticoagulation to aspirin after 
successful RFCA of AF, based on CHADS2, CHA2DS2-
VASc, HAS-BLED scores, and recommended a standard 
rhythm monitoring follow-up strategy. The present study 
suggested that switching warfarin to aspirin 3 months after 
RFCA could be as safe and efficacious as continuous antico-
agulation even in patients with a CHA2DS2-VASc score ≥2. 
However, strict and continuous rhythm monitoring and main-
tenance of optimal INR should be emphasized to achieve 
these results. We also proved that CHA2DS2-VASc and 
HAS-BLED scores were very valuable parameters in pre-
dicting ischemic stroke and hemorrhagic complications, 
even after RFCA of AF. 
Risk and benefits of anticoagulation in patients with 
non-valvular AF
Although warfarin can significantly reduce stroke risk by 
64% in patients with non-valvular AF,19 it still has an annu-
al 1.6--2.4% risk of stroke or systemic embolism and an an-
nual 3.1--3.4% risk of major hemorrhagic complications.11-13 
Moreover, the annual risk of fatal hemorrhagic stroke is be-
tween 0.7--0.8%.11-13 Therefore, the 2010 ESC guidelines 
recommended caution, regular review, and correction of re-
versible bleeding risk factors for patients with a HAS-BLED 
score ≥3.5 In this study, 2 out of 721 patients experienced 
intracranial and spinal cord hemorrhages during anticoagu-
lation, but they were not included in this analysis because 
these complications occurred within 3 months after RFCA. 
Although aspirin has a lower potential risk of major bleed-
ing than warfarin, it reduces ischemic stroke risk by no more 
than 22% as compared with the 64% risk reduction achieved 
by anticoagulation.19 Therefore, aspirin can be considered 
in patients with a very low AF burden and a high HAS-
BLED score. However, a previous study reported that the 
risk of intracranial hemorrhage was similar in patients tak-
ing aspirin to those taking warfarin, and that aspirin in-
creases bleeding risk significantly when administered si-
multaneously with warfarin.20 In a large cohort study from 
Denmark including over 132000 patients with AF, warfarin 
was superior for stroke prevention and similar for bleeding 
risk compared to aspirin.21 Aspirin has rather higher bleed-
ing risk than warfarin in Japan Atrial Fibrillation Stroke Tri-
al (JAST).22 Discrepancies of current study from these two 
studies were that we included the patients with significantly 
reduced AF burden by catheter ablation, and those with 
young and low CHADS2 score. Generally, the risk of bleed-
ing (HAS-BLED score) increases parallel with the risk of 
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Korea under the Ministry of Education, Science and Tech-
nology of the Republic of Korea.
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pean Cardiac Arrhythmia Society (ECAS); and in collaboration 
with the American College of Cardiology (ACC), American Heart 
Association (AHA), the Asia Pacific Heart Rhythm Society 
(APHRS), and the Society of Thoracic Surgeons (STS). Endorsed 
by the governing bodies of the American College of Cardiology 
Foundation, the American Heart Association, the European Cardiac 
Arrhythmia Society, the European Heart Rhythm Association, the 
Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Soci-
the time of stroke or TIA in patients with thromboembolic 
complications. We might miss asymptomatic AF recurrence 
or non-cardioembolic source of stroke in these patients. 
Careful monitoring for rhythm is important in patients with 
high CHA2DS2-VASc or high HAS-BLED scores and pa-
tients at high risk of AF recurrence, such as those with high 
LA volume, PeAF, or long ablation time.34 In this study, we 
suggest that a regular rhythm monitoring strategy based on 
the current guidelines was acceptable for making a clinical 
decision of switching warfarin to aspirin. We also implied 
that CHA2DS2-VASc and HAS-BLED scores were still in-
dependent predictors for stroke/TIA and major hemorrhage 
after successful catheter ablation of AF. 
Study limitations 
This study was designed as a retrospective observational 
study, but not as a randomized study. Although CHADS2 
and CHA2DS2-VASc scores were not significantly different 
between two groups, past history of stroke or TIA were 
higher in W group than in ASA group. It may be because 
the physicians tended to continue warfarin in patients with 
a history of stroke or TIA. Although we tried to follow the 
consensus guidelines for AF rhythm monitoring strictly, all 
silent recurrence of AF could not be detected on surface 
ECG or Holter monitoring. The time in therapeutic range 
was relatively low (44.2%) in the W group compared to pre-
vious large scale clinical trials, and it could be one of factors 
for no significant differences in thromboembolic complica-
tion between W group and ASA group. Although recovery of 
LA contractile function is an important factor for prediction 
of thromboembolic events, we did not analyze LA contrac-
tile function in the current study.
In conclusion, after successful RFCA of AF, switching 
warfarin to aspirin 3 months after RFCA could be as safe 
and efficacious as long-term anticoagulation, even in pa-
tients with CHA2DS2-VASc score ≥2. Strict heart rhythm 
monitoring in the aspirin group and careful INR monitoring 
in the anticoagulation group are important in patients after 
RFCA of AF. Future large randomized trials are warranted. 
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